Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node
Background Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowled...
Gespeichert in:
| Veröffentlicht in: | Journal for immunotherapy of cancer Jg. 7; H. 1; S. 133 - 14 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
22.05.2019
BioMed Central Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Schlagworte: | |
| ISSN: | 2051-1426, 2051-1426 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN.
Methods
Viable LN cells from BrC SLN (
n
= 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN,
n
= 17). Findings were related to clinicopathological characteristics.
Results
Our data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival.
Conclusion
These data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. |
|---|---|
| AbstractList | Background Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN. Methods Viable LN cells from BrC SLN (n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics. Results Our data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival. Conclusion These data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. Keywords: Dendritic cell, Sentinel lymph node, Immune suppression, Breast cancer BackgroundImmune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN.MethodsViable LN cells from BrC SLN (n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics.ResultsOur data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival.ConclusionThese data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. Background Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN. Methods Viable LN cells from BrC SLN ( n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics. Results Our data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival. Conclusion These data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. Abstract Background Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN. Methods Viable LN cells from BrC SLN (n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics. Results Our data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival. Conclusion These data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN. Viable LN cells from BrC SLN (n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics. Our data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival. These data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN.BACKGROUNDImmune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN.Viable LN cells from BrC SLN (n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics.METHODSViable LN cells from BrC SLN (n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics.Our data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival.RESULTSOur data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival.These data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. .CONCLUSIONThese data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. . Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN. Viable LN cells from BrC SLN (n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics. Our data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival. These data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. . |
| ArticleNumber | 133 |
| Audience | Academic |
| Author | Vuylsteke, Ronald J.C.L.M. van den Tol, Petrousjka M. van de Ven, Rieneke Stockmann, Hein B.A.C. van Pul, Kim M. de Gruijl, Tanja D. te Velde, Elisabeth A. Rutgers, Emiel J. Th |
| Author_xml | – sequence: 1 givenname: Kim M. surname: van Pul fullname: van Pul, Kim M. organization: Departments of Medical and Surgical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam – sequence: 2 givenname: Ronald J.C.L.M. surname: Vuylsteke fullname: Vuylsteke, Ronald J.C.L.M. organization: Department of Surgery, Spaarne Gasthuis – sequence: 3 givenname: Rieneke surname: van de Ven fullname: van de Ven, Rieneke organization: Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam – sequence: 4 givenname: Elisabeth A. surname: te Velde fullname: te Velde, Elisabeth A. organization: Department of Surgical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam – sequence: 5 givenname: Emiel J. Th surname: Rutgers fullname: Rutgers, Emiel J. Th organization: Department of Surgery, The Netherlands Cancer Institute – sequence: 6 givenname: Petrousjka M. surname: van den Tol fullname: van den Tol, Petrousjka M. organization: Department of Surgical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam – sequence: 7 givenname: Hein B.A.C. surname: Stockmann fullname: Stockmann, Hein B.A.C. organization: Department of Surgery, Spaarne Gasthuis – sequence: 8 givenname: Tanja D. orcidid: 0000-0003-1464-8978 surname: de Gruijl fullname: de Gruijl, Tanja D. email: td.degruijl@vumc.nl organization: Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31118093$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uttq3DAQNSWlSdN8QF-KoFD64lQXX-SXQgi9BAJ9aPosZGm8VrClrWQH9pf6lR3vpsluaIvBHs-cc0Y6nJfZkQ8esuw1o-eMyepDKmjBy5yyJqcVLXP2LDvhtGQ5K3h1tFcfZ2cp3VJKGRVCSvkiOxYMJWgjTrJf32EAM7k7GDak1-MaIliil46eXPAkdGTYjOue-GAhj5CcBT8RfNnoJmeIgWFIZB3BgIWlCF2YvSU32wlJ8xpnKS1aGtsjTDpNemEmHGhLnCdTD6TFnzQRo72BSBIucR6GveWvsuedHhKc3X9Psx-fP91cfs2vv325ury4zk0liikH1khW0oYC0EaWsmJWAmWt0XUhWiprg85QXchKthZEzYBDa6u2FK1mtjLiNLva6dqgb9U6ulHHjQraqW0jxJXSEc8_gGo5b0sjeQGtLspln6amM9JgIWohUOvjTms9tyNYg7eKejgQPZx416tVuFNVKShtChR4fy8Qw88Z0qRGlxZjtYcwJ8W54IxSXjYIffsEehvm6NEqxSshGeOyEI-olcYLON8F3GsWUXWBZpWc17JC1PlfUPhYGJ3BIHYO-weEd3uEHvQw9SkM85KhdAh8s-_IgxV_IokAtgOYGFKK0D1AGFVL8tUu-QqTr5bkK4ac-gnHuGmbXzy2G_7L5DsmhtH5FcRH0_5N-g1F9RhU |
| CitedBy_id | crossref_primary_10_1186_s12957_024_03404_7 crossref_primary_10_1016_j_lfs_2019_116920 crossref_primary_10_1038_s41416_023_02473_x crossref_primary_10_3389_fonc_2025_1636942 crossref_primary_10_1136_jitc_2022_005079 crossref_primary_10_1002_advs_202400524 crossref_primary_10_1016_j_banm_2021_11_025 crossref_primary_10_1158_1078_0432_CCR_24_3135 crossref_primary_10_1097_MNM_0000000000001737 crossref_primary_10_1016_j_ajpath_2021_05_006 crossref_primary_10_1016_j_trecan_2025_04_008 crossref_primary_10_1007_s10549_023_07230_5 crossref_primary_10_1007_s10555_025_10278_y crossref_primary_10_3390_cancers13164005 crossref_primary_10_3389_fmed_2025_1539024 crossref_primary_10_1111_joa_14147 crossref_primary_10_1016_j_it_2021_07_003 crossref_primary_10_1007_s00262_022_03223_3 crossref_primary_10_3389_fimmu_2024_1449291 crossref_primary_10_3390_cancers14184505 crossref_primary_10_1016_j_bcp_2023_115731 crossref_primary_10_3390_ijms22179401 crossref_primary_10_1155_2022_7291406 crossref_primary_10_1038_s41467_020_17046_2 crossref_primary_10_1007_s00262_020_02792_5 crossref_primary_10_3389_fimmu_2025_1674174 crossref_primary_10_2340_1651_226X_2024_33008 crossref_primary_10_1007_s13402_023_00873_y crossref_primary_10_1155_2021_5516399 crossref_primary_10_3389_fimmu_2021_643291 crossref_primary_10_1002_eji_202250325 crossref_primary_10_1136_jitc_2023_008378 crossref_primary_10_1007_s00262_024_03754_x crossref_primary_10_1080_2162402X_2023_2201147 crossref_primary_10_1111_joa_14251 crossref_primary_10_3389_fbioe_2024_1445829 crossref_primary_10_3390_vaccines12040355 crossref_primary_10_1136_jitc_2021_003623 crossref_primary_10_1126_sciimmunol_abg3551 crossref_primary_10_3390_cells10030627 crossref_primary_10_1016_j_ebiom_2024_105271 crossref_primary_10_1016_j_addr_2024_115485 crossref_primary_10_3390_cancers16162881 crossref_primary_10_1002_adma_202412141 crossref_primary_10_1186_s12957_024_03454_x crossref_primary_10_3389_fbioe_2023_1242126 crossref_primary_10_3390_lymphatics3020013 crossref_primary_10_1038_s41392_023_01576_4 |
| Cites_doi | 10.1007/s00262-010-0833-1 10.1158/0008-5472.CAN-12-4100 10.1155/2011/430394 10.1158/1078-0432.CCR-11-2701 10.1200/JCO.2012.46.1574 10.1158/2326-6066.CIR-17-0110 10.1158/0008-5472.CAN-03-3251 10.1038/nri3175 10.1084/jem.20092140 10.1371/journal.pone.0127028 10.1007/s00262-003-0485-5 10.1158/1078-0432.CCR-06-3045 10.1371/journal.pmed.0020284 10.1634/theoncologist.2009-0078 10.1200/JCO.2014.58.1967 10.1038/nrclinonc.2015.215 10.1007/s00262-008-0523-4 10.1186/1471-2407-9-231 10.1038/35021093 10.1158/2159-8274.CD-10-0028 10.1016/j.imlet.2013.11.021 10.1084/jem.20111457 10.1084/jem.20100348 10.1016/S0002-9440(10)64152-1 10.1002/cncr.21729 10.1038/bjc.2013.634 10.1158/1541-7786.MCR-08-0107 10.1038/nri1919 10.1186/bcr808 10.1084/jem.20092618 10.4161/onci.20171 10.1016/j.ejso.2007.05.013 10.1200/JCO.2010.30.5037 10.1182/blood-2011-03-344838 10.1007/s10555-010-9247-y 10.1007/BF02523635 10.1158/0008-5472.CAN-14-2386 10.1158/2326-6066.CIR-14-0165 10.1007/s00428-011-1145-3 10.1038/nri1498 10.1016/S0140-6736(05)66544-0 10.1016/j.ejca.2009.03.024 10.1046/j.1524-4741.2000.98114.x 10.1158/1078-0432.CCR-17-0944 10.1111/j.0105-2896.2004.00142.x 10.1093/annonc/mdu112 10.1016/j.jim.2004.04.025 10.1038/ncomms12150 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. 2019 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s40425-019-0605-1 |
| DatabaseName | Springer Nature OA Free Journals (WRLC) CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_b22b5c824eba45e098a0cfc8c98a3733 PMC6530094 A586522786 31118093 10_1186_s40425_019_0605_1 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Stichting A Sister's Hope funderid: http://dx.doi.org/10.13039/501100008382 – fundername: KWF Kankerbestrijding grantid: KWF VU2015-7864; KWF VU2015-7864 funderid: http://dx.doi.org/10.13039/501100004622 – fundername: ; – fundername: ; grantid: KWF VU2015-7864; KWF VU2015-7864 |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ADBBV ADRAZ AFKRA AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RMJ ROL RPM RSV SOJ UKHRP AAYXX AFFHD CITATION -A0 3V. ABDBF ACRMQ ADINQ ADUKV ALIPV C24 NPM 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c634t-e19815090ee0985861d8e01bca743b087c2050a4868bde371e2ebd6b53ba1d6c3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 57 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000468928600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2051-1426 |
| IngestDate | Fri Oct 03 12:29:33 EDT 2025 Tue Nov 04 01:56:50 EST 2025 Sun Nov 09 12:22:47 EST 2025 Tue Oct 07 07:10:54 EDT 2025 Tue Nov 11 10:05:13 EST 2025 Tue Nov 04 17:43:30 EST 2025 Thu May 22 21:09:15 EDT 2025 Thu Jan 02 22:59:27 EST 2025 Tue Nov 18 21:43:04 EST 2025 Sat Nov 29 03:12:23 EST 2025 Sat Sep 06 07:27:22 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Immune suppression Dendritic cell Breast cancer Sentinel lymph node |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c634t-e19815090ee0985861d8e01bca743b087c2050a4868bde371e2ebd6b53ba1d6c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-1464-8978 |
| OpenAccessLink | https://doaj.org/article/b22b5c824eba45e098a0cfc8c98a3733 |
| PMID | 31118093 |
| PQID | 2638112843 |
| PQPubID | 2040222 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b22b5c824eba45e098a0cfc8c98a3733 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6530094 proquest_miscellaneous_2232100259 proquest_journals_2638112843 gale_infotracmisc_A586522786 gale_infotracacademiconefile_A586522786 gale_healthsolutions_A586522786 pubmed_primary_31118093 crossref_primary_10_1186_s40425_019_0605_1 crossref_citationtrail_10_1186_s40425_019_0605_1 springer_journals_10_1186_s40425_019_0605_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-22 |
| PublicationDateYYYYMMDD | 2019-05-22 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationTitleAbbrev | j. immunotherapy cancer |
| PublicationTitleAlternate | J Immunother Cancer |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (605_CR1) 2005; 365 D Gabrilovich (605_CR11) 2004; 4 F Andre (605_CR5) 2013; 19 DI Gabrilovich (605_CR10) 2012; 12 MAE Watanabe (605_CR42) 2010; 29 A Bembenek (605_CR17) 2008; 34 R. van de Ven (605_CR26) 2011; 118 P Savas (605_CR33) 2016; 13 A Pinto (605_CR35) 2012; 1 V Guarneri (605_CR4) 2009; 14 Hans Torrenga (605_CR27) 2004; 11 A Bachem (605_CR38) 2010; 207 C Denkert (605_CR9) 2015; 33 AS Mansfield (605_CR19) 2009; 9 R Dent (605_CR3) 2007; 13 LF Poulin (605_CR36) 2010; 207 X Hu (605_CR31) 2009; 7 DG DeNardo (605_CR6) 2011; 1 MFCM Hout van den (605_CR39) 2017; 5 C Bergenfelz (605_CR43) 2015; 10 A Seo (605_CR47) 2013; 109 RJCLM Vuylsteke (605_CR23) 2002; 161 C Ghirelli (605_CR40) 2015; 75 S Loi (605_CR8) 2014; 25 HE Kohrt (605_CR18) 2005; 2 CM Perou (605_CR32) 2000; 406 L Galluzzi (605_CR46) 2012; 11 R Nakamura (605_CR14) 2009; 45 RR Huang (605_CR22) 2002; 6 AS Mansfield (605_CR15) 2011; 459 E Segura (605_CR25) 2012; 209 I Gingras (605_CR7) 2015; 13 NJ Poindexter (605_CR16) 2004; 6 S Mahmoud (605_CR48) 2011; 29 BD Koster (605_CR50) 2017; 23 B Elliott (605_CR24) 2004; 291 S Satthaporn (605_CR45) 2004; 53 V Bronte (605_CR29) 2016; 7 RJCLM Vuylsteke (605_CR41) 2004; 64 N Janikashvili (605_CR12) 2011; 2011 AJ Cochran (605_CR13) 2006; 6 K Matsuura (605_CR20) 2006; 106 CM Diaz-montero (605_CR28) 2009; 58 O Metzger-Filho (605_CR2) 2013; 31 SL Jongbloed (605_CR37) 2010; 207 WR Heath (605_CR34) 2004; 199 J Duraiswamy (605_CR30) 2013; 73 G Schreibelt (605_CR44) 2010; 59 Z Faghih (605_CR21) 2014; 158 BJR Sluijter (605_CR49) 2015; 3 |
| References_xml | – volume: 59 start-page: 1573 issue: 10 year: 2010 ident: 605_CR44 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0833-1 – volume: 73 start-page: 3591 issue: 12 year: 2013 ident: 605_CR30 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-4100 – volume: 2011 year: 2011 ident: 605_CR12 publication-title: Clin Dev Immunol doi: 10.1155/2011/430394 – volume: 19 start-page: 28 issue: 1 year: 2013 ident: 605_CR5 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-2701 – volume: 31 start-page: 3083 issue: 25 year: 2013 ident: 605_CR2 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.46.1574 – volume: 5 start-page: 969 issue: 11 year: 2017 ident: 605_CR39 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-17-0110 – volume: 64 start-page: 8456 issue: 22 year: 2004 ident: 605_CR41 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-3251 – volume: 12 start-page: 253 issue: 4 year: 2012 ident: 605_CR10 publication-title: Nat Rev Immunol doi: 10.1038/nri3175 – volume: 207 start-page: 1247 issue: 6 year: 2010 ident: 605_CR37 publication-title: J Exp Med doi: 10.1084/jem.20092140 – volume: 10 start-page: 5 year: 2015 ident: 605_CR43 publication-title: PLoS One doi: 10.1371/journal.pone.0127028 – volume: 53 start-page: 510 issue: 6 year: 2004 ident: 605_CR45 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-003-0485-5 – volume: 13 start-page: 4429 issue: 15 year: 2007 ident: 605_CR3 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-3045 – volume: 2 start-page: 0904 issue: 9 year: 2005 ident: 605_CR18 publication-title: PLoS Med doi: 10.1371/journal.pmed.0020284 – volume: 14 start-page: 645 issue: 7 year: 2009 ident: 605_CR4 publication-title: Oncologist. doi: 10.1634/theoncologist.2009-0078 – volume: 33 start-page: 983 issue: 9 year: 2015 ident: 605_CR9 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.1967 – volume: 13 start-page: 228 issue: 4 year: 2016 ident: 605_CR33 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2015.215 – volume: 11 start-page: 215 issue: 3 year: 2012 ident: 605_CR46 publication-title: Nat Rev – volume: 58 start-page: 49 issue: 1 year: 2009 ident: 605_CR28 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0523-4 – volume: 9 start-page: 231 year: 2009 ident: 605_CR19 publication-title: BMC Cancer doi: 10.1186/1471-2407-9-231 – volume: 406 start-page: 747 issue: 6797 year: 2000 ident: 605_CR32 publication-title: Nature. doi: 10.1038/35021093 – volume: 1 start-page: 54 issue: 1 year: 2011 ident: 605_CR6 publication-title: Cancer Discov doi: 10.1158/2159-8274.CD-10-0028 – volume: 158 start-page: 57 issue: 1–2 year: 2014 ident: 605_CR21 publication-title: Immunol Lett doi: 10.1016/j.imlet.2013.11.021 – volume: 209 start-page: 653 issue: 4 year: 2012 ident: 605_CR25 publication-title: J Exp Med doi: 10.1084/jem.20111457 – volume: 207 start-page: 1273 issue: 6 year: 2010 ident: 605_CR38 publication-title: J Exp Med doi: 10.1084/jem.20100348 – volume: 161 start-page: 19 issue: 1 year: 2002 ident: 605_CR23 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)64152-1 – volume: 106 start-page: 1227 issue: 6 year: 2006 ident: 605_CR20 publication-title: Cancer. doi: 10.1002/cncr.21729 – volume: 109 start-page: 2705 issue: 10 year: 2013 ident: 605_CR47 publication-title: Br J Cancer doi: 10.1038/bjc.2013.634 – volume: 7 start-page: 511 issue: 4 year: 2009 ident: 605_CR31 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-08-0107 – volume: 6 start-page: 659 issue: 9 year: 2006 ident: 605_CR13 publication-title: Nat Rev Immunol. doi: 10.1038/nri1919 – volume: 6 start-page: R408 issue: 4 year: 2004 ident: 605_CR16 publication-title: Breast Cancer Res doi: 10.1186/bcr808 – volume: 207 start-page: 1261 issue: 6 year: 2010 ident: 605_CR36 publication-title: J Exp Med doi: 10.1084/jem.20092618 – volume: 1 start-page: 726 issue: 5 year: 2012 ident: 605_CR35 publication-title: Oncoimmunology. doi: 10.4161/onci.20171 – volume: 34 start-page: 514 issue: 5 year: 2008 ident: 605_CR17 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2007.05.013 – volume: 29 start-page: 1949 issue: 15 year: 2011 ident: 605_CR48 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.30.5037 – volume: 13 start-page: 372 issue: 6 year: 2015 ident: 605_CR7 publication-title: Clin Adv Hematol Oncol – volume: 118 start-page: 2502 issue: 9 year: 2011 ident: 605_CR26 publication-title: Blood doi: 10.1182/blood-2011-03-344838 – volume: 29 start-page: 569 issue: 4 year: 2010 ident: 605_CR42 publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-010-9247-y – volume: 11 start-page: 231S issue: S3 year: 2004 ident: 605_CR27 publication-title: Annals of Surgical Oncology doi: 10.1007/BF02523635 – volume: 75 start-page: 2775 issue: 14 year: 2015 ident: 605_CR40 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-2386 – volume: 3 start-page: 495 issue: 5 year: 2015 ident: 605_CR49 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0165 – volume: 459 start-page: 391 issue: 4 year: 2011 ident: 605_CR15 publication-title: Virchows Arch doi: 10.1007/s00428-011-1145-3 – volume: 4 start-page: 941 issue: 12 year: 2004 ident: 605_CR11 publication-title: Nat Rev Immunol. doi: 10.1038/nri1498 – volume: 365 start-page: 1687 issue: 9472 year: 2005 ident: 605_CR1 publication-title: Lancet. doi: 10.1016/S0140-6736(05)66544-0 – volume: 45 start-page: 2123 issue: 12 year: 2009 ident: 605_CR14 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2009.03.024 – volume: 6 start-page: 225 issue: 4 year: 2002 ident: 605_CR22 publication-title: Breast J doi: 10.1046/j.1524-4741.2000.98114.x – volume: 23 start-page: 5679 issue: 19 year: 2017 ident: 605_CR50 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-0944 – volume: 199 start-page: 9 year: 2004 ident: 605_CR34 publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2004.00142.x – volume: 25 start-page: 1544 issue: 8 year: 2014 ident: 605_CR8 publication-title: Ann Oncol doi: 10.1093/annonc/mdu112 – volume: 291 start-page: 71 issue: 1–2 year: 2004 ident: 605_CR24 publication-title: J Immunol Methods doi: 10.1016/j.jim.2004.04.025 – volume: 7 year: 2016 ident: 605_CR29 publication-title: Nat Commun doi: 10.1038/ncomms12150 |
| SSID | ssj0001033888 |
| Score | 2.3720238 |
| Snippet | Background
Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN),... Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the... Background Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN),... BackgroundImmune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN),... Abstract Background Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 133 |
| SubjectTerms | Adjuvant chemotherapy Antigens Breast cancer Cancer Cancer metastasis Cancer treatment Care and treatment Chemotherapy Clinical/Translational Cancer Immunotherapy Dendritic cell Dendritic cells Flow cytometry Genetic aspects Hormones Hospitals Immune suppression Immunology Immunotherapy Lymphatic system Lymphocytes Mastectomy Medical prognosis Medical research Medicine Medicine & Public Health Metastasis Oncology Pathology Research Article Sentinel lymph node Surgery T cells Tumor-infiltrating lymphocytes Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLagQ4gX7pfAACMhIYGiJbGTOE9oQ5t4oZpgSHuzfOtWqSQlSZH2l_iVnOO47TLEXnipovi4td3Pn4_tcyHkrQEczBwvY8dZEnMLc64SoohVWZagXjsMgOKTTZTTqTg9rY7DgVsXzCrXnOiJ2jYGz8j3oI5IkUzZx-XPGLNG4e1qSKFxk-xgpDI-ITsHh9Pjr9tTlgS2YEKE68xUFHsdR5jCDhqd7zEK52hB8nH7_2bnS8vTVdPJK_enflk6uve_HbpP7gaFlO4PCHpAbrj6Ibn9JVy5PyK_v_lMOUCKiwt6rkDLbp2l6A4xHObSZkYXF4AJWjfWxbB7xzSlPYUP69MoULwb6OgSqNVZhw_NDHM50RNfQrvVMhjj1lTB6x-uV-jmBDWh0wBBOq8pqKlUo_18Tw3itKXoNAUNXFz68cfk-9HhyafPcUjwEJuC8T52aSVAIa0S55JK5KJIrXBJqo0CvUYnojRZkieKi0Jo61iZusxpW-icaZXawrAnZFI3tXtGaI6KpuU57B9z7gQusil8KyutUYprE5Fk_S9LE6KfYxKOhfS7IFHIARgSgCERGDKNyPtNleUQ-uM64QOEzkYQo3b7F017JgMJSJ1lOjci404rnmOfVWJmRhh4YCVjEXmNwJODC-yGe-Q-DE2OPstFRN55CWQfaL5RwYkCBgHjeI0kd0eSwBpmXLxGpQys1cktJCPyZlOMNdESr3bNCmQy9PoCTbmKyNNhLmw6zVIMKFhB7XI0S0ajMi6p5-c-pnmRMzRyjciH9XzaNuufg_78-k68IHcyP8_zOMt2yaRvV-4luWV-9fOufRWo4g-COnJm priority: 102 providerName: ProQuest – databaseName: Springer LINK dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3ZbtQw0IKCUF-4oYECRkJCAkUksZ14Hwui4oUK0YL6ZvmYbVdaktUmi9Rf4iuZcbLbphwSvERRPE5sz-l4DsZeeKSDKcgqBSmyVAbkuYnWZWqrqkLzGigBSiw2UR0c6OPjyachjrtde7uvjySjpI5srcs3rST6wq0vRc1T-syr7BpqO03c-Pnw6_mPlQx3XVoPJ5i_7TnSQTFV_68C-YJGuuwteenINGqi_Vv_NYfb7OZgePK9nlLusCtQ32U3Pg5H6_fYj8NYEQeF3_yMn1q0ppcQOIU99D9teTPl8zPEPa-bACnu0qkcacfxEmK5BE5nAC1foAiFAHTTTKlmEz-KLbxdLQan25pbfPwNOkvhTNgTZ4Gkxmc1R3OUO_KT77gnelxyCo7CAc4vfPw--7L__ujdh3Qo5JD6UsguhRzRhLjKABBhSpd50JDlzlu0X1ymK19kKrNSl9oFEFUOBbhQOiWczUPpxQO2VTc17DCuyKAMUuE-UUnQpExzfKuogrdWOp-wbI1a44cs51RsY27ibkeXpseBQRwYwoHJE_Zq02XRp_j4G_BbopcNIGXnjg-a5YkZmN24onDK60KCs1LRnG3mp157vBGVEAl7RtRm-lDXjYwxe7g0imKTy4S9jBAkZXD43g7BErgIlK9rBLk7gkTp4MfNa4o2g3RqDfKfzskwwZE83zRTT_K4q6FZIUxB0V1oEU8S9rBngM2kRU6JAyfYuxqxxmhVxi317DTmLi-VIGfWhL1eM8j5sP646I_-Cfox2y4ih6m0KHbZVrdcwRN23X_vZu3yaRQWPwFuaGaO priority: 102 providerName: Springer Nature |
| Title | Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node |
| URI | https://link.springer.com/article/10.1186/s40425-019-0605-1 https://www.ncbi.nlm.nih.gov/pubmed/31118093 https://www.proquest.com/docview/2638112843 https://www.proquest.com/docview/2232100259 https://pubmed.ncbi.nlm.nih.gov/PMC6530094 https://doaj.org/article/b22b5c824eba45e098a0cfc8c98a3733 |
| Volume | 7 |
| WOSCitedRecordID | wos000468928600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: RBZ dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: 7X7 dateStart: 20130501 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: BENPR dateStart: 20130501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: PIMPY dateStart: 20130501 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer LINK customDbUrl: eissn: 2051-1426 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: RSV dateStart: 20131201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1db9Mw0IKBEC-IbwKjGAkJCRQtH3bsPG5oEzysqraBypPlr2qVSlK1KdL-Er-SOycNzRDwwkuUxHZ6vTuf7-z7IOSNBT6YeSZiz_IkZg7mXCllEWshBKjXHhOghGITYjyW02k52Sn1hT5hbXrgFnEHJssMtzJj3mjGfVJKndiZlRZucpGHPJ-g9ewYU2F3JQHTS8ruGDOVxcGaIXuC5YxB95h9c7AQhXz9v0vlnWXpusvktXPTsByd3Cf3Oj2SHrbwPyA3fPWQ3DntTsofkR_nocANyLLFFb3UoByvvKMYxdDuwdJ6RhdXQEpa1c7HYHRjddGGwsWF6gcUt_TXdAkS0TuPN_UMSzDRi9BC15tl50NbUQ2vv_lGY3QSjASYgXPovKKgXVKDbu8NtcheK4qxTgDgYufHH5PPJ8cXHz7GXV2G2BY5a2KflhL0yDLxSA4ui9RJn6TGalBHTCKFzRKeaCYLaZzPReozb1xheG506gqbPyF7VV35Z4Ry1A8d42D2ceYlro0pfDUXzmrNjI1IsiWSsl3ScqydsVDBeJGFaumqgK4K6arSiLzrhyzbjB1_63yElO87YrLt8AJYUHUsqP7FghF5hXyj2sjVXmSoQ0ANx1DjIiJvQw8UGgC-1V3sAyAB028Neu4PesJkt8PmLW-qTtisFUwnmaKeAZC87ptxJDrQVb7eQJ8Mg7VAwS0j8rRl5f5P5ynmASxhtBgw-QArw5ZqfhlSkRc8R9_UiLzfTodfYP0R6c__B9JfkLtZmMw8zrJ9stesNv4luW2_N_P1akRuiqkIVzkit46Ox5OzUZAQ8DT5dDr5Ck9n519-AiE8abM |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3LbtQw0CoFARfej0ChRgIhFUVN4iR2DgiVR9Wq7QqJIu3NOLaXrrQkyyYL2l_iwDcy4yS7TRG99cBlFcXjxJmdpz0PQp5roIORjblvYxb4sQGey4RIfcU5B_PaYgEU12yCDwZiOMw-rpHfXS4MhlV2MtEJalNq3CPfhjkiRGHK3ky_-9g1Ck9XuxYaDVkc2MVPcNmq1_vv4f99EUW7H47f7fltVwFfpyyufQtuNlhBWWBtkIlEpKERNghzrUCZ5oHgOgqSQMUiFbmxjIc2srlJ84TlKjSpZvDcS-QyyHGOIWR8yFd7OgE4fEK0h6ehSLerGJkC_HVM9ceanz3157oE_K0LTinDs4GaZ05rnRLcvfm_oe8WudGa23Sn4Y_bZM0Wd8jVozag4C759cn1AQKRP1nQEwU-xMwaiskezVY1LUd0sgCKp0VprD-z2N20qCn8GNckguLJR0WnoDissXhRjrBTFT12I7SaT9tQ44IquP3N1gqTuGAmIBkYjI4LCkY4zTE7oKYauXBGMSUMFjg59fJ75POFYOo-WS_Kwj4kNEEz2sQJeMdJbAWaECE8lXGjlYpz7ZGgoyqp29ru2GJkIp2PJ1LZEKIEQpRIiDL0yNZyyrQpbHIe8Fsk1SUg1iR3N8rZV9mKOJlHUZ5oEcU2V3GC36wCPdJCwwXjjHlkEwldNgm-S8kqdwA1CWZkpx556SBQtsLytWpTRAAJWKWsB7nRgwSZqPvDHRfIViZXcsUCHnm2HMaZGGdY2HIOMBHmtIEfkHnkQcN7y49mIZZLzGA273FlDyv9kWJ84iq2pwnDEF6PvOr4d7WsfyL90fkfsUmu7R0fHcrD_cHBY3I9cjIm8aNog6zXs7l9Qq7oH_W4mj11QoqSLxfN1n8ADozM-A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGhiZeuF8CgxkJhASKmouTOA8IDUZFNVZVYkjbk3Fsl1UqSUlSUP8SP4FfxzlO2i5D7G0PvFRRbOdyer5zic-FkGcK-GBsWOIaFnou04C5lPPYlUmSgHltsACKbTaRDIf8-DgdbZDfy1wYDKtcykQrqHWh8Bt5D9ZwH4Vp2Bu3YRGj_f6b2XcXO0jhTuuynUbDIgdm8RPct-r1YB_-6-dB0H9_9O6D23YYcFUcsto14HKDRZR6xngpj3jsa248P1MSFGvm8UQFXuRJxmOeaRMmvglMpuMsCjPp61iFcN0rZAtMcgYY2xoNDkcn6y88Hrh_nLdbqT6PexVDiID3jon_WAG0owxtz4C_NcMZ1Xg-bPPc3q1Vif0b_zMxb5LrrSFO9xrk3CIbJr9Ntg_bUIM75Ncn2yEIlMF0QU8leBel0RTTQJqP2LQY0-kCsEDzQhu3NNj3NK8p_GjbPoLinkhFZ6BSjDZ4UIyxhxU9siO0ms_aIOScSjj9zdQS07tgJRAcoEcnOQXznGaYN1BThfgsKSaLwQNOz9z8Lvl8KZS6RzbzIjcPCI3QwNYsAr85YoajceHDVcNEKylZphziLTlMqLbqOzYfmQrr_fFYNEwpgCkFMqXwHfJytWTWlDy5aPJbZNvVRKxWbk8U5VfRCj-RBUEWKR4wk0kW4TtLT40VV3AQJmHokF1ketGk_q5krtgD0kSYqx075IWdgVIXHl_JNnkEiID1yzozdzozQVqq7vASEaKV1pVYw8EhT1fDuBIjEHNTzGFOgNlu4CGkDrnf4HD10qGPhRRTWJ10ENqhSnckn5zaWu5xFGJwr0NeLbG8fqx_Ev3hxS-xS7YBzeLjYHjwiFwLrLiJ3CDYIZt1OTePyVX1o55U5ZNWYlHy5bJx_QfV6ddH |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Selectively+hampered+activation+of+lymph+node-resident+dendritic+cells+precedes+profound+T+cell+suppression+and+metastatic+spread+in+the+breast+cancer+sentinel+lymph+node&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=van+de+Ven%2C+Rieneke&rft.au=Vuylsteke%2C+Ronald+J.C.L.M&rft.au=van+den+Tol%2C+Petrousjka+M&rft.au=de+Gruijl%2C+Tanja+D&rft.date=2019-05-22&rft.pub=BioMed+Central+Ltd&rft.issn=2051-1426&rft.eissn=2051-1426&rft.volume=7&rft.issue=1&rft_id=info:doi/10.1186%2Fs40425-019-0605-1&rft.externalDBID=n%2Fa&rft.externalDocID=A586522786 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon |